With Americans concerned about the rising cost of drugs, there is growing scrutiny on Capitol Hill of the various practices in the pharmaceutical supply chain and how they contribute to costs. Lawmakers at the state and national level are mulling bills that would regulate practices by various players. Meanwhile, several large pharmacy benefit managers are in the process of merging with large insurance companies, raising questions about how consolidation in the industry will affect consumers.
Join POLITICO for a deep-dive conversation on the state of the pharmaceutical supply chain and what can be done to better control costs.
The program will begin with welcome remarks from Pfizer CEO Ian Read on behalf of PhRMA.